BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zheng C, Huang D, Bergenbrant S, Sundblad A, Österborg A, Björkholm M, Holm G, Yi Q. Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma: Cytokine Polymorphism in Multiple Myeloma. British Journal of Haematology 2000;109:39-45. [DOI: 10.1046/j.1365-2141.2000.01963.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Alexander DD, Mink PJ, Adami H, Cole P, Mandel JS, Oken MM, Trichopoulos D. Multiple myeloma: A review of the epidemiologic literature. Int J Cancer 2007;120:40-61. [DOI: 10.1002/ijc.22718] [Cited by in Crossref: 183] [Cited by in F6Publishing: 154] [Article Influence: 13.1] [Reference Citation Analysis]
2 Couriel DR, Hicks K, Giralt S, Champlin RE. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation: . Current Opinion in Oncology 2000;12:582-7. [DOI: 10.1097/00001622-200011000-00011] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 2.5] [Reference Citation Analysis]
3 Xu J, Yin Z, Cao S, Gao W, Liu L, Yin Y, Liu P, Shu Y. Systematic review and meta-analysis on the association between IL-1B polymorphisms and cancer risk. PLoS One. 2013;8:e63654. [PMID: 23704929 DOI: 10.1371/journal.pone.0063654] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
4 Hwang IR, Kodama T, Kikuchi S, Sakai K, Peterson LE, Graham DY, Yamaoka Y. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology. 2002;123:1793-1803. [PMID: 12454835 DOI: 10.1053/gast.2002.37043] [Cited by in Crossref: 262] [Cited by in F6Publishing: 254] [Article Influence: 13.8] [Reference Citation Analysis]
5 Seidemann K, Zimmermann M, Book M, Meyer U, Burkhardt B, Welte K, Reiter A, Stanulla M. Tumor Necrosis Factor and Lymphotoxin Alfa Genetic Polymorphisms and Outcome in Pediatric Patients With Non-Hodgkin’s Lymphoma: Results From Berlin-Frankfurt-Münster Trial NHL-BFM 95. JCO 2005;23:8414-21. [DOI: 10.1200/jco.2005.01.2179] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
6 Zheng C, Huang D, Liu L, Wu R, Bergenbrant Glas S, Osterborg A, Björkholm M, Holm G, Yi Q, Sundblad A. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 2001;95:184-8. [PMID: 11307152 DOI: 10.1002/1097-0215(20010520)95:3<184::aid-ijc1031>3.0.co;2-v] [Cited by in Crossref: 32] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
7 Granero Farias M, Andrade Dos Santos C, de Mello Vicente B, Habigzang M, de Oliveira da Silva P, Emerim Lemos N, Dieter C, Paz A, Esteves Daudt L. The effects of gene polymorphisms on susceptibility to acute GVHD and survival of allogeneic HSCT recipients: IL-10 gene polymorphisms as a more accessible target to predict prognosis. Hum Immunol 2020;81:18-25. [PMID: 31889553 DOI: 10.1016/j.humimm.2019.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Tian G, Mi J, Wei X, Zhao D, Qiao L, Yang C, Li X, Zhang S, Li X, Wang B. Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci Rep 2015;5:11394. [PMID: 26096712 DOI: 10.1038/srep11394] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
9 Skerrett DL, Moore EM, Bernstein DS, Vahdat L. Cytokine Genotype Polymorphisms in Breast Carcinoma: Associations of TGF-β1 with Relapse. Cancer Investigation 2009;23:208-14. [DOI: 10.1081/cnv-200055954] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
10 Iacopetta B, Grieu F, Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004;90:419-22. [PMID: 14735187 DOI: 10.1038/sj.bjc.6601545] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.6] [Reference Citation Analysis]
11 Zhang J, Sun X, Xiao L, Xie C, Xuan D, Luo G. Gene polymorphisms and periodontitis: Gene polymorphisms. Periodontology 2000 2011;56:102-24. [DOI: 10.1111/j.1600-0757.2010.00371.x] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
12 Uchiyama K, Naito K, Tsuchida M, Takai K, Okayama N, Fujimura K, Hinoda Y. Impact of a genetic polymorphism of the interleukin-1 receptor antagonist on technique survival in peritoneal dialysis patients. Blood Purif 2005;23:450-8. [PMID: 16244470 DOI: 10.1159/000088988] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
13 Rauert H, Stühmer T, Bargou R, Wajant H, Siegmund D. TNFR1 and TNFR2 regulate the extrinsic apoptotic pathway in myeloma cells by multiple mechanisms. Cell Death Dis 2011;2:e194. [PMID: 21850048 DOI: 10.1038/cddis.2011.78] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 4.6] [Reference Citation Analysis]
14 Dring AM, Davies FE, Rollinson SJ, Roddam PL, Rawstron AC, Child JA, Jack AS, Morgan GJ. Interleukin 6, tumour necrosis factor α and lymphotoxin α polymorphisms in monoclonal gammopathy of uncertain significance and multiple myeloma: Correspondence. British Journal of Haematology 2001;112:249-50. [DOI: 10.1046/j.1365-2141.2001.02497-2a.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
15 Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA. Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 2009;18:282-8. [PMID: 19124510 DOI: 10.1158/1055-9965.EPI-08-0778] [Cited by in Crossref: 28] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
16 Yao M, Brummer G, Acevedo D, Cheng N. Cytokine Regulation of Metastasis and Tumorigenicity. Adv Cancer Res. 2016;132:265-367. [PMID: 27613135 DOI: 10.1016/bs.acr.2016.05.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 7.4] [Reference Citation Analysis]
17 Li B, Wang XD, Sun X, Ma J, Yang Y, Ma X. Lack of association between TNF-α promoter polymorphisms and multiple myeloma: a meta-analysis. Leuk Res 2013;37:50-7. [PMID: 22999526 DOI: 10.1016/j.leukres.2012.08.027] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
18 Aladzsity I, Kovács M, Semsei A, Falus A, Szilágyi A, Karádi I, Varga G, Füst G, Várkonyi J. Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 2009;33:1570-3. [PMID: 19406470 DOI: 10.1016/j.leukres.2009.03.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
19 Brown EE, Lan Q, Zheng T, Zhang Y, Wang SS, Hoar-zahm S, Chanock SJ, Rothman N, Baris D. Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 2007;120:2715-22. [DOI: 10.1002/ijc.22618] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 1.6] [Reference Citation Analysis]
20 Abazis-stamboulieh D, Oikonomou P, Papadoulis N, Panayiotidis P, Vrakidou E, Tsezou A. Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leukemia & Lymphoma 2009;48:2196-203. [DOI: 10.1080/10428190701615892] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
21 Haukim N, Bidwell JL, Smith AJ, Keen LJ, Gallagher G, Kimberly R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J. Cytokine gene polymorphism in human disease: on-line databases, supplement 2. Genes Immun. 2002;3:313-330. [PMID: 12209358 DOI: 10.1038/sj.gene.6363881] [Cited by in Crossref: 155] [Cited by in F6Publishing: 151] [Article Influence: 8.6] [Reference Citation Analysis]
22 Bayley JP, Ottenhoff TH, Verweij CL. Is there a future for TNF promoter polymorphisms? Genes Immun 2004;5:315-29. [PMID: 14973548 DOI: 10.1038/sj.gene.6364055] [Cited by in Crossref: 176] [Cited by in F6Publishing: 164] [Article Influence: 11.0] [Reference Citation Analysis]
23 Lim CS, Zheng S, Kim YS, Ahn C, Han JS, Kim S, Lee JS, Chae D. THE −174 G TO C POLYMORPHISM OF INTERLEUKIN-6 GENE IS VERY RARE IN KOREANS. Cytokine 2002;19:52-4. [DOI: 10.1006/cyto.2002.1951] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
24 Chikanza I, Akpenyi O. Association of Monoclonal Gammopathy of Undetermined Significance with Behcet's Disease: A Review of Shared Common Disease Pathogenetic Mechanisms. Mediterr J Rheumatol 2018;29:80-5. [PMID: 32185304 DOI: 10.31138/mjr.29.2.80] [Reference Citation Analysis]
25 Dong X, Zhang Z, Shou L, Shen J. Interleukin-6 gene-174 G/C promoter polymorphism is not associated with multiple myeloma susceptibility: evidence from meta-analysis: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24647. [PMID: 33578591 DOI: 10.1097/MD.0000000000024647] [Reference Citation Analysis]
26 Harun-Or-Roshid M, Ali MB, Jesmin, Mollah MNH. Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk. PLoS One 2021;16:e0247055. [PMID: 33684135 DOI: 10.1371/journal.pone.0247055] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Chakraborty B, Vishnoi G, Gowda SH, Goswami B. Interleukin-6 gene-174 G/C promoter polymorphism and its association with clinical profile of patients with multiple myeloma. Asia Pac J Clin Oncol. 2017;13:e402-e407. [PMID: 25359504 DOI: 10.1111/ajco.12290] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
28 Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH. The -238 tumor necrosis factor-alpha promoter polymorphism is associated with decreased susceptibility to cancers. Cancer Lett. 2001;166:41-46. [PMID: 11295285 DOI: 10.1016/s0304-3835(01)00438-4] [Cited by in Crossref: 117] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
29 Zhai R, Liu G, Yang C, Huang C, Wu C, Christiani DC. The G to C polymorphism at -174 of the interleukin-6 gene is rare in a Southern Chinese population: . Pharmacogenetics 2001;11:699-701. [DOI: 10.1097/00008571-200111000-00008] [Cited by in Crossref: 59] [Cited by in F6Publishing: 52] [Article Influence: 3.0] [Reference Citation Analysis]
30 He M, Yang W, Zhang M, Lian Y, Hua H, Zeng J, Zhang L. Association between interleukin-6 gene promoter −572C/G polymorphism and the risk of sporadic Alzheimer’s disease. Neurol Sci 2010;31:165-8. [DOI: 10.1007/s10072-009-0199-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
31 Hsieh YY, Chang CC, Tsai FJ, Wu JY, Shi YR, Tsai HD, Tsai CH. Polymorphisms for interleukin-1 beta (IL-1 beta)-511 promoter, IL-1 beta exon 5, and IL-1 receptor antagonist: nonassociation with endometriosis. J Assist Reprod Genet 2001;18:506-11. [PMID: 11665666 DOI: 10.1023/a:1016653127262] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
32 Du J, Yuan Z, Zhang C, Fu W, Jiang H, Chen B, Hou J. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res 2010;34:1453-8. [PMID: 20122728 DOI: 10.1016/j.leukres.2010.01.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
33 Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, Min ZC, Tao J, Li PC, Zhang W, Wu HF, Zhang ZD, Wang ZJ, Hua LX, Feng NH, Wang XR. IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 2011;38:2589-96. [PMID: 21104146 DOI: 10.1007/s11033-010-0399-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
34 Morgan GJ, Davies FE, Linet M. Myeloma aetiology and epidemiology. Biomed Pharmacother 2002;56:223-34. [PMID: 12199621 DOI: 10.1016/s0753-3322(02)00194-4] [Cited by in Crossref: 52] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
35 Benke KS, Carlson MC, Doan BQ, Walston JD, Xue QL, Reiner AP, Fried LP, Arking DE, Chakravarti A, Fallin MD. The association of genetic variants in interleukin-1 genes with cognition: findings from the cardiovascular health study. Exp Gerontol 2011;46:1010-9. [PMID: 21968104 DOI: 10.1016/j.exger.2011.09.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
36 Peng X, Shi J, Sun W, Ruan X, Guo Y, Zhao L, Wang J, Li B. Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis. Oncotarget 2018;9:12351-64. [PMID: 29552316 DOI: 10.18632/oncotarget.24033] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
37 Zhou L, Zheng Y, Tian T, Liu K, Wang M, Lin S, Deng Y, Dai C, Xu P, Hao Q, Kang H, Dai Z. Associations of interleukin-6 gene polymorphisms with cancer risk: Evidence based on 49,408 cancer cases and 61,790 controls. Gene 2018;670:136-47. [PMID: 29842912 DOI: 10.1016/j.gene.2018.05.104] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
38 Nielsen KR, Rodrigo-domingo M, Steffensen R, Baech J, Bergkvist KS, Oosterhof L, Schmitz A, Bødker JS, Johansen P, Vogel U, Vangsted A, Dybkær K, Bøgsted M, Johnsen HE. Interactions between SNPs affecting inflammatory response genes are associated with multiple myeloma disease risk and survival. Leukemia & Lymphoma 2017;58:2695-704. [DOI: 10.1080/10428194.2017.1306643] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
39 Freeman BD, Buchman TG, McGrath S, Tabrizi AR, Zehnbauer BA. Template-directed dye-terminator incorporation with fluorescence polarization detection for analysis of single nucleotide polymorphisms implicated in sepsis. J Mol Diagn 2002;4:209-15. [PMID: 12411588 DOI: 10.1016/S1525-1578(10)60705-2] [Cited by in Crossref: 11] [Article Influence: 0.6] [Reference Citation Analysis]
40 Bown MJ, Weston S, Horsburgh T, Nicholson ML, Bell PR, Sayers RD. A comparison of methods for determining genotypes at the tumour necrosis factor-alpha-308, interleukin (IL)-1beta+3953, IL-6 -174 and IL-10 -1082/-819/-592 polymorphic loci. Int J Immunogenet 2005;32:83-90. [PMID: 15787640 DOI: 10.1111/j.1744-313X.2005.00494.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Shahzad MN, Ijaz I, Naqvi SSZH, Yan C, Lin F, Li S, Huang C. Association between interleukin gene polymorphisms and multiple myeloma susceptibility. Mol Clin Oncol 2020;12:212-24. [PMID: 32064097 DOI: 10.3892/mco.2020.1979] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Yamin C, Duarte JA, Oliveira JM, Amir O, Sagiv M, Eynon N, Sagiv M, Amir RE. IL6 (-174) and TNFA (-308) promoter polymorphisms are associated with systemic creatine kinase response to eccentric exercise. Eur J Appl Physiol 2008;104:579-86. [PMID: 18758806 DOI: 10.1007/s00421-008-0728-4] [Cited by in Crossref: 46] [Cited by in F6Publishing: 39] [Article Influence: 3.5] [Reference Citation Analysis]
43 Ziakas PD, Karsaliakos P, Prodromou ML, Mylonakis E. Interleukin-6 polymorphisms and hematologic malignancy: a re-appraisal of evidence from genetic association studies. Biomarkers 2013;18:625-31. [DOI: 10.3109/1354750x.2013.840799] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
44 Sekuri C, Cam FS, Sagcan A, Ercan E, Tengiz I, Alioglu E, Berdeli A. No association of interleukin-6 gene polymorphism (-174 G/C) with premature coronary artery disease in a Turkish cohort. Coronary Artery Disease 2007;18:333-7. [DOI: 10.1097/mca.0b013e32820588ae] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
45 Vangsted AJ, Klausen TW, Ruminski W, Gimsing P, Andersen NF, Gang AO, Abildgaard N, Knudsen LM, Nielsen JL, Gregersen H. The polymorphism IL-1beta T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant. 2009;43:539-545. [PMID: 18997828 DOI: 10.1038/bmt.2008.351] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
46 Matos MF, Lourenço DM, Orikaza CM, Bajerl JA, Noguti MA, Morelli VM. The role of IL-6, IL-8 and MCP-1 and their promoter polymorphisms IL-6 -174GC, IL-8 -251AT and MCP-1 -2518AG in the risk of venous thromboembolism: a case-control study. Thromb Res 2011;128:216-20. [PMID: 21620438 DOI: 10.1016/j.thromres.2011.04.016] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
47 Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica 2007;92:960-9. [PMID: 17606447 DOI: 10.3324/haematol.11011] [Cited by in Crossref: 103] [Cited by in F6Publishing: 94] [Article Influence: 7.4] [Reference Citation Analysis]
48 Junli W, Wenjun H, Jinxin L, Legen N, Yesheng W, Fenglian Y. Association of IL-6 polymorphisms with gastric cancer risk: Evidences from a meta-analysis. Cytokine 2012;59:176-83. [DOI: 10.1016/j.cyto.2012.03.032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
49 Hosgood HD 3rd, Baris D, Zhang Y, Berndt SI, Menashe I, Morton LM, Lee KM, Yeager M, Zahm SH, Chanock S, Zheng T, Lan Q. Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res 2009;33:1609-14. [PMID: 19362737 DOI: 10.1016/j.leukres.2009.03.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
50 Ryu JH, Kim SJ. Interleukin-6 -634 C/G and -174 G/C polymorphisms in Korean patients undergoing hemodialysis. Korean J Intern Med 2012;27:327-37. [PMID: 23019398 DOI: 10.3904/kjim.2012.27.3.327] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
51 Gebregziabher M, Bernstein L, Wang Y, Cozen W. Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States). Cancer Causes Control 2006;17:931-8. [PMID: 16841260 DOI: 10.1007/s10552-006-0030-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
52 Kádár K, Kovács M, Karádi I, Melegh B, Pocsai Z, Mikala G, Tordai A, Szilágyi A, Adány R, Füst G, Várkonyi J. Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 2008;32:1499-504. [PMID: 18405969 DOI: 10.1016/j.leukres.2008.03.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
53 Hong Y, Yu J, Wang G, Qiao W. Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis. Hematology 2019;24:216-24. [PMID: 31793411 DOI: 10.1080/16078454.2018.1552341] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Vangsted A, Klausen TW, Vogel U. Genetic variations in multiple myeloma I: effect on risk of multiple myeloma. Eur J Haematol 2012;88:8-30. [PMID: 21883480 DOI: 10.1111/j.1600-0609.2011.01700.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
55 Mazur G, Bogunia-kubik K, Wróbel T, Karabon L, Polak M, Kuliczkowski K, Lange A. IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunology Letters 2005;96:241-6. [DOI: 10.1016/j.imlet.2004.08.015] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 2.4] [Reference Citation Analysis]
56 Au WY, Fung A, Wong KF, Chan CH, Liang R. Tumor necrosis factor alpha promoter polymorphism and the risk of chronic lymphocytic leukemia and myeloma in the Chinese population. Leukemia & Lymphoma 2009;47:2189-93. [DOI: 10.1080/10428190600758645] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
57 Li Y, Du Z, Wang X, Wang G, Li W. Association of IL-6 Promoter and Receptor Polymorphisms with Multiple Myeloma Risk: A Systematic Review and Meta-Analysis. Genet Test Mol Biomarkers. 2016;20:587-596. [PMID: 27525545 DOI: 10.1089/gtmb.2015.0169] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]